ES2965460T3 - Método automatizable para el aislamiento de ácidos nucleicos - Google Patents
Método automatizable para el aislamiento de ácidos nucleicos Download PDFInfo
- Publication number
- ES2965460T3 ES2965460T3 ES16732490T ES16732490T ES2965460T3 ES 2965460 T3 ES2965460 T3 ES 2965460T3 ES 16732490 T ES16732490 T ES 16732490T ES 16732490 T ES16732490 T ES 16732490T ES 2965460 T3 ES2965460 T3 ES 2965460T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleic acids
- butanol
- nucleic acid
- isolation
- purification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 217
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 216
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 216
- 238000000034 method Methods 0.000 title claims abstract description 79
- 238000002955 isolation Methods 0.000 title claims abstract description 55
- 238000000746 purification Methods 0.000 claims abstract description 41
- 239000012472 biological sample Substances 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 52
- 230000003196 chaotropic effect Effects 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 32
- 239000007858 starting material Substances 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 31
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 210000002381 plasma Anatomy 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 108091005804 Peptidases Proteins 0.000 claims description 18
- 239000004365 Protease Substances 0.000 claims description 18
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 18
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 14
- 238000002405 diagnostic procedure Methods 0.000 claims description 12
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 10
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 10
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methylbutan-1-ol Chemical compound CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 claims description 6
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical group SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- MXLMTQWGSQIYOW-UHFFFAOYSA-N 3-methyl-2-butanol Chemical compound CC(C)C(C)O MXLMTQWGSQIYOW-UHFFFAOYSA-N 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 239000012149 elution buffer Substances 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 3
- 230000035790 physiological processes and functions Effects 0.000 claims description 3
- 150000003567 thiocyanates Chemical class 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 11
- 230000002797 proteolythic effect Effects 0.000 abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
- 239000000523 sample Substances 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 28
- 238000000605 extraction Methods 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 20
- 239000011536 extraction buffer Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 235000019419 proteases Nutrition 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- -1 e.g. Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 150000001298 alcohols Chemical class 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000006920 protein precipitation Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 6
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241001115402 Ebolavirus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000011528 liquid biopsy Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102200055464 rs113488022 Human genes 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220197820 rs121913227 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15171261 | 2015-06-09 | ||
| PCT/EP2016/063150 WO2016198519A1 (en) | 2015-06-09 | 2016-06-09 | Automatable method for nucleic acid isolation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2965460T3 true ES2965460T3 (es) | 2024-04-15 |
Family
ID=53373331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16732490T Active ES2965460T3 (es) | 2015-06-09 | 2016-06-09 | Método automatizable para el aislamiento de ácidos nucleicos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10829758B2 (https=) |
| EP (2) | EP3307907B1 (https=) |
| JP (1) | JP6815334B2 (https=) |
| CN (1) | CN107683335A (https=) |
| CA (1) | CA2982706A1 (https=) |
| ES (1) | ES2965460T3 (https=) |
| WO (1) | WO2016198519A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108138366A (zh) | 2015-07-23 | 2018-06-08 | 比奥卡尔齐斯股份有限公司 | 优化的临床样品测序 |
| EP4303311A3 (en) * | 2017-09-18 | 2024-04-03 | Phase Scientific International, Ltd. | Method for using aqueous two-phase system for the isolation, purification and/or concentration of short nucleic acid fragments |
| EP3884066A2 (en) * | 2018-11-19 | 2021-09-29 | Biocartis NV | Enhanced detection of low-copy-number nucleic acids in an integrated workflow |
| CN114450419A (zh) * | 2019-08-08 | 2022-05-06 | 拜奥卡蒂斯生物股份有限公司 | 新型核酸纯化化学物质 |
| WO2021130415A1 (en) * | 2019-12-23 | 2021-07-01 | Biopsense Oy | Method, automated system and cartridge for extraction of cell-free nucleic acids from a blood sample |
| EP4684011A1 (en) * | 2023-03-20 | 2026-01-28 | Bioecho Life Sciences GmbH | Method for isolating nucleic acid from a biological sample |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8900725A (nl) | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
| DE4321904B4 (de) * | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen |
| DE19746874A1 (de) | 1997-10-23 | 1999-04-29 | Qiagen Gmbh | Verfahren zur Isolierung und Reinigung von Nukleinsäuren an hydrophoben Oberflächen - insbesondere unter Verwendung hydrophober Membranen |
| GB2346615B (en) * | 1998-11-17 | 2003-10-15 | Cambridge Molecular Tech | Isolating nucleic acid |
| DE60137203D1 (de) * | 2000-03-24 | 2009-02-12 | Qiagen Gmbh | Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung |
| EP1633869A1 (en) * | 2003-06-04 | 2006-03-15 | Qiagen AS | Method for sequentially isolating dna and rna from the same nucleic acid-containing sample |
| JP2005137298A (ja) * | 2003-11-07 | 2005-06-02 | Fuji Photo Film Co Ltd | 核酸の分離精製方法 |
| EP1690938A1 (de) * | 2005-02-11 | 2006-08-16 | Qiagen GmbH | Verfahren zur Isolierung von Nukleinsäuren, wobei die Nukleinsäuren bei erhöhter Temperatur an einer Matrix immobilisiert werden |
| US8703476B2 (en) | 2005-06-30 | 2014-04-22 | Biocartis Sa | Cartridge for automated medical diagnostics |
| JP2007325562A (ja) * | 2006-06-09 | 2007-12-20 | Fujifilm Corp | 核酸抽出法 |
| EP2128169A1 (de) | 2008-05-30 | 2009-12-02 | Qiagen GmbH | Verfahren zur Isolierung von kurzkettigen Nukleinsäuren |
| DE102008026058A1 (de) * | 2008-05-30 | 2009-12-03 | Qiagen Gmbh | Lyse, Binde- und/oder Waschreagenz verwendbar zur Isolierung und/oder Reinigung von Nukleinsäuren |
| EP2264168B1 (de) * | 2009-06-18 | 2014-12-17 | Qiagen GmbH | Verfahren zur Isolierung von Nukleinsäuren |
| EP2345719A1 (en) | 2010-01-18 | 2011-07-20 | Qiagen GmbH | Method for isolating small RNA |
| EP2742152B1 (en) * | 2011-08-12 | 2017-04-12 | Qiagen GmbH | Method for isolating nucleic acids |
| EP2770056B1 (en) * | 2012-07-18 | 2017-05-31 | Zymo Research Corporation | Nucleic acid purification |
| EP2971032B1 (en) | 2013-03-15 | 2019-05-08 | Abbott Molecular Inc. | Compositions and methods for nucleic acid extraction |
-
2016
- 2016-06-09 JP JP2017563581A patent/JP6815334B2/ja active Active
- 2016-06-09 EP EP16732490.4A patent/EP3307907B1/en active Active
- 2016-06-09 ES ES16732490T patent/ES2965460T3/es active Active
- 2016-06-09 US US15/570,947 patent/US10829758B2/en active Active
- 2016-06-09 CA CA2982706A patent/CA2982706A1/en active Pending
- 2016-06-09 WO PCT/EP2016/063150 patent/WO2016198519A1/en not_active Ceased
- 2016-06-09 CN CN201680030749.8A patent/CN107683335A/zh active Pending
- 2016-06-09 EP EP22216565.6A patent/EP4186980A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3307907C0 (en) | 2023-11-15 |
| EP3307907B1 (en) | 2023-11-15 |
| EP3307907A1 (en) | 2018-04-18 |
| WO2016198519A1 (en) | 2016-12-15 |
| US20180291367A1 (en) | 2018-10-11 |
| JP6815334B2 (ja) | 2021-01-20 |
| JP2018518171A (ja) | 2018-07-12 |
| US10829758B2 (en) | 2020-11-10 |
| EP4186980A1 (en) | 2023-05-31 |
| CA2982706A1 (en) | 2016-12-15 |
| CN107683335A (zh) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2965460T3 (es) | Método automatizable para el aislamiento de ácidos nucleicos | |
| ES2716114T3 (es) | Sistema y procedimiento para recoger una muestra de ácido nucleico | |
| ES2720435T3 (es) | Método y dispositivo para la recolección y amplificación de ácidos nucleicos circulantes | |
| ES2954252T3 (es) | Matrices y dispositivos de recogida de muestras basados en proteínas | |
| ES2938752T3 (es) | Método, solución de lisis y kit para la reducción selectiva de ácidos nucleicos animales en una muestra | |
| ES2588227T3 (es) | Composiciones, métodos y kits para aislar ácidos nucleicos de fluidos corporales usando medios de intercambio aniónico | |
| ES2937410T3 (es) | Método rápido para aislar ácidos nucleicos extracelulares | |
| ES2877602T3 (es) | Materiales de captura de polinucleótidos y procedimientos de uso de los mismos | |
| ES2320875T5 (es) | Procedimientos y materiales para utilizar compuestos químicos como herramienta para el almacenamiento de ácidos nucleicos sobre medios de sistemas de purificación de ácidos nucleicos | |
| ES2665252T3 (es) | Purificación de ácido nucleico de microorganismos a partir de muestras del hospedador | |
| ES2321492T3 (es) | Aislamiento y purificacion de acidos nucleicos. | |
| DK2588609T3 (en) | METHOD AND KIT FOR SEQUENTIAL ISOLATION OF NUCLEOTIDE SPECIES FROM A SAMPLE | |
| JP4435787B2 (ja) | タンパク質を変性させるための処方物および方法 | |
| JP2017520268A (ja) | Ｒｎａを高収率で単離するための方法 | |
| US20040126796A1 (en) | Extraction of DNA from biological samples | |
| ES2819903T3 (es) | Aislamiento de ácidos nucleicos | |
| CN117413058A (zh) | 用于纯化核酸，特别是在微流体装置中纯化核酸的方法 | |
| ES2665280T3 (es) | Métodos para la extracción y purificación de componentes de muestras biológicas | |
| ES3057312T3 (en) | Methods for amplifying nucleic acids on substrates | |
| HK40085645A (en) | Automatable method for nucleic acid isolation | |
| BR102022019150A2 (pt) | Kit e método para extração e purificação de ácidos nucleicos | |
| WO2022077128A1 (es) | Dispositivo para extracción y purificación de ácidos nucleicos |